CES1 Crossover Trial of Clopidogrel and Ticagrelor
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 111 participants.
Also called NCT03161678
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 111 participants
- Registry
-
NCT03161678
-
- Other papers using this trial's data
- Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03161678. Randomized; no masking; primary purpose basic science. Start 2017-08-22 (actual); primary completion 2022-12-12 (actual). Results posted on 2024-05-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CES1 Crossover Trial of Clopidogrel and Ticagrelor
- Condition
- Myocardial Infarction
- Condition
- Thrombosis
- Condition
- Platelet Dysfunction
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Ticagrelor
- Lead sponsor
- University of Maryland, Baltimore
Record details
- Record id
cardio:ct-nct03161678- Content hash
c08edf44d835001f9548237282b8e15a039bb5bdc8f07df98b1df7a86c38e0f3